SCHEMBL21270

SCHEMBL21270

CC(C)c1ccccc1B(O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.54
GABRB2 P47870 2/20 0.54
GABRG2 P18507 2/20 0.50
GABRB3 P28472 2/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 2/20 0.50
FAAH O00519 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
GABRB1 P18505 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
HTR2C P28335 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50
HTR2B P41595 1/20 0.50
GABRA2 P47869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430856 1.00 GABRA1 (0.54) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL16379272 0.85 GABRA1 (0.50) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL29468969 0.85 ENPP2 (0.41) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL12640622 0.85 ENPP2 (0.41) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL2247879 0.82 ENPP2 (0.43) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL24478328 0.81 GABRA1 (0.48) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL4652041 0.81 GABRA1 (0.48) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL28105050 0.81 GABRA1 (0.67) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL29951757 0.80 ENPP2 (0.41) GABRA1GABRB2GABRG2GABRB3LMNA
SCHEMBL4013443 0.80 ENPP2 (0.41) GABRA1GABRB2GABRG2GABRB3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111171721-B Ceramizable ablation-resistant coating and preparation method thereof 西安近代化学研究所 2021-08-20 CN claimed
CN-111171721-A Ceramizable ablation-resistant coating and preparation method thereof 西安近代化学研究所 2020-05-19 CN claimed
CN-109467662-A A kind of RTM type boron bakelite resin and preparation method thereof 北京玻钢院复合材料有限公司 2019-03-15 CN claimed
CN-109456571-A A kind of heat molten type boron bakelite resin and preparation method thereof 北京玻钢院复合材料有限公司 2019-03-12 CN claimed
CN-105086351-B A kind of hot melt phenolic resin preimpregnation material and preparation method thereof 西安交通大学 2018-07-17 CN claimed
CN-105086351-A Hot-melting phenolic resin prepreg and preparation method thereof UNIV XI AN JIAOTONG 2015-11-25 CN claimed
CN-103289033-B Containing aryl boron bakelite resin and preparation method thereof XI'AN JIAOTONG UNIVERSITY (CN) 2015-10-28 CN claimed
CN-122079945-A Coumarin derivative containing substituted phenyl ether structure, preparation method and application thereof 2026-05-26 CN disclosed
CN-122059933-A Pyrazolo [4,3-d ] pyrimidinone derivative and preparation method and application thereof 中国科学院新疆理化技术研究所 2026-05-19 CN disclosed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 US disclosed
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds ACERTA PHARMA B.V. (NL) 2026-05-05 US disclosed
EP-4727924-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION ONO Pharmaceutical Co., Ltd. (JP) 2026-04-22 EP disclosed
EP-4713319-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-03-25 EP disclosed
EP-1124822-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2002-04-03 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed
EP-1124822-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2001-08-22 EP disclosed
EP-1097158-A2 LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-05-09 EP disclosed
WO-2000026211-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2000-05-11 WO disclosed
WO-2000002887-A2 LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS GABRA1 3509/4885GABRB2 4258/4885GABRG2 2998/4885
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds MEN1, PKD1, PKD2 GABRA1 2298/4885GABRB2 1892/4885GABRG2 3350/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 GABRA1 1921/4885GABRB2 2401/4885GABRG2 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.